Oculis SA
Next Generation of Topical Ophthalmic Treatments
Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients.
Oculis' novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.
The Company's leading clinical candidates are:
- OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone based on Oculis' proprietary Solubilizing Nanoparticle (SNP) technology.
- OCS-02 is a novel topical anti-TNF alpha antibody.
In addition, Oculis' formulation discovery focus and capabilities are enabling the development of topical drugs targeting sight-threatening diseases.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
01.06.2026
Oculis cancels plans to seek approval for OCS-1 for diabetic macular oedema (startupticker.ch)
21.04.2026
Three Swiss biotechs secure regulatory and clinical milestones (startupticker.ch)
11.02.2026
Seven new startups awarded Scale-up Vaud Label (startupticker.ch)
08.01.2026
Significant Advances in Pharmaceutical Pipelines for Underserved Diseases (startupticker.ch)
31.10.2025
Financial success for publicly traded biotech companies (startupticker.ch)
No milestones
No Jobs
Videos
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Oculis SA
Next Generation of Topical Ophthalmic Treatments
Website:
www.oculis.com
Headquarter:
Foundation Date:
December 2017
Technology:
- Biotech
Sectors:
- Biotech
Support received
